United States

Lpath Inc (LPTN.OQ)

LPTN.OQ on NASDAQ Stock Exchange Capital Market

2 Dec 2016
Change (% chg)

$0.07 (+2.77%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for LPTN.OQ


Lpath, Inc. is a biotechnology company. The Company is focused on the discovery and development of lipidomic-based therapeutic antibodies. The Company's product candidates include iSONEP, ASONEP and Lpathomab. The Company utilizes ImmuneY2 technology for the production of its antibodies. iSONEP is the ocular formulation of... (more)
No analyst recommendations are available for LPTN.OQ.


Beta: 0.27
Market Cap(Mil.): $6.61
Shares Outstanding(Mil.): 2.40
Dividend: --
Yield (%): --


  LPTN.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -4.46 -- --
ROI: -143.26 -1.09 14.95
ROE: -143.30 -2.39 16.29

BRIEF-Apollo Endosurgery and Lpath sign merger agreement

* Apollo security holders are expected to own approximately 95.8 percent of combined company

Sep 08 2016

BRIEF-Lpath files for mixed shelf of up to $10 mln - SEC filing

* Files for mixed shelf of up to $10 million - SEC filing Source text for Eikon: Further company coverage:

Aug 22 2016

BRIEF-Lpath awarded department of defense grant

* Lpath awarded department of defense grant for traumatic brain injury pain study

Jun 20 2016

BRIEF-Lpath announces 1-for-14 reverse stock split

* Number of common shares outstanding will be decreased from approximately 33.1 million pre-split to 2.36 million shares post-split

Jun 09 2016

Earnings vs. Estimates